Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B-Reference-Cited by-同舟云学术

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

Author:

Mancuso Maria Elisa¹,Lubetsky Aaron²,Pan‐Petesch Brigitte³,Lissitchkov Toshko⁴,Nagao Azusa⁵,Seifert Wilfried⁶,Li Yanyan⁷,Santagostino Elena¹

Affiliation:

1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

2. The Israeli National Haemophilia Center Chaim Sheba Medical Center Tel Hashomer Israel

3. Centre Hospitalier Régional Universitaire de Brest Hôpital A. Morvan Brest France

4. Department of Coagulation Disorders and Anemia Specialized Hospital for Active Treatment Joan Pavel Sofia Bulgaria

5. Department of Blood Coagulation Ogikubo Hospital Tokyo Japan

6. CSL Behring Marburg Germany

7. CSL Behring King of Prussia PA USA

Funder

CSL Behring

Publisher

Wiley

Subject

Hematology

Link

Reference29 articles.

4. Outcome in moderate haemophilia;Uijl I;Blood Transfus,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Clinical features and treatment of hemophilia B;Pediatric Hematology/Oncology and Immunopathology;2024-04-18